Pages that link to "Q35847448"

The following pages link to Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha (Q35847448):

Displaying 34 items.

• Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study (Q30435188) (← links)
• Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia (Q33711127) (← links)
• Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype (Q34488720) (← links)
• Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms (Q34519513) (← links)
• Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy (Q34870833) (← links)
• Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia (Q35153656) (← links)
• New Therapeutic Approaches for Waldenstrom Macroglobulinemia (Q35176177) (← links)
• Novel agents in Waldenström macroglobulinemia. (Q35429544) (← links)
• Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes (Q35625192) (← links)
• Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia (Q35951586) (← links)
• Novel agents in Waldenstrom Macroglobulinemia (Q36117791) (← links)
• Follicular lymphoma: today's treatments and tomorrow's targets (Q36521854) (← links)
• Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma. (Q36689790) (← links)
• Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L. (Q37005060) (← links)
• Therapy-related myeloid leukemia. (Q37009760) (← links)
• Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy (Q37231130) (← links)
• A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas (Q37364653) (← links)
• Long-Term Complications of Lymphoma and Its Treatment (Q37864001) (← links)
• High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study (Q40063998) (← links)
• Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial (Q40374056) (← links)
• Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. (Q41444373) (← links)
• Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. (Q42852282) (← links)
• Therapy-related myelodysplasia and fludarabine combination therapy – do the benefits justify the risk? (Q42881033) (← links)
• Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients (Q42905792) (← links)
• Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). (Q44668352) (← links)
• Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records (Q46704590) (← links)
• A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. (Q48371948) (← links)
• Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography. (Q53058794) (← links)
• Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis (Q61873060) (← links)
• Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial (Q80166499) (← links)
• Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Q82487185) (← links)
• Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide (Q84579465) (← links)
• Myelodysplastic syndromes (Q87492688) (← links)
• Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma (Q90478489) (← links)